Literature DB >> 1611688

Improvement of stability and dissolution of prostaglandin E1 by maltosyl-beta-cyclodextrin in lyophilized formulation.

M Yamamoto1, F Hirayama, K Uekama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1611688     DOI： 10.1248/cpb.40.747

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN： 0009-2363            Impact factor:   1.645


× No keyword cloud information.
  4 in total

Review 1.  Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.

Authors:  Yongmei Wu; Jaquan Levons; Ajit S Narang; Krishnaswamy Raghavan; Venkatramana M Rao
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

2.  PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).

Authors:  Vivek Gupta; Marauo Davis; Louisa J Hope-Weeks; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2011-04-06       Impact factor: 4.200

3.  NMR studies of the inclusion complex of cloprostenol sodium salt with beta-cyclodextrin in aqueous solution.

Authors:  Hyun Suk Whang; Franck A P Vendeix; Hanna S Gracz; John Gadsby; Alan Tonelli
Journal:  Pharm Res       Date:  2007-12-05       Impact factor: 4.200

4.  Osteotropic beta-cyclodextrin for local bone regeneration.

Authors:  Xin-Ming Liu; Andrew T Wiswall; John E Rutledge; Mohammed P Akhter; Diane M Cullen; Richard A Reinhardt; Dong Wang
Journal:  Biomaterials       Date:  2008-01-15       Impact factor: 12.479
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.